BlogNews and press

alveofit® joins QureOS from Qure.ai to Strengthen Primary Care in Global Health

3 min readUpdated 11 September 2025

alveoair spirometer and app, with "Welcome to QureOS" from Qure.ai

alveofit® is pleased to collaborate with Qure.ai, bringing its AI-powered, cloud-connected respiratory health solution to a broader global platform. With advanced spirometry devices, real-time lung function insights, and remote monitoring, alveofit® empowers early detection and effective management of conditions like asthma and COPD. This partnership strengthens our mission to make precision respiratory care more accessible across hospitals, clinics, wellness programs, and community health initiatives to QureOS, the AI-powered digital health Operating System for global healthcare.

QureOS, Qure.ai's platform for healthcare AI, brings together applications from proven innovators worldwide across various disease areas including maternal and child health, infectious diseases, lung health and non-communicable disease such as cancer. It has been designed to address the barriers of trying and adopting healthcare AI in Low- and Middle-Income Countries (LMICs). It aims to improve access to healthcare digitisation to strengthen primary care, aid triage, allocate resources efficiently and improve patient care.

Qure.ai has seen firsthand how health systems worldwide are overburdened, under-equipped and resource constrained. With a footprint in more than 90 countries, at 3800 sites and tackling TB screening with AI at scale, it has witnessed the power of artificial intelligence to be the health equity equalizer. Now, it is aiming to replicate this success across multi-disease areas with multiple platform partners.

Mr. Phungreiso Varu, Vice President – Public Health at alveofit®, states, “Our partnership with QureOS marks a major leap forward in advancing AI-driven respiratory care. By integrating with this powerful platform, alveofit® will accelerate its technological capabilities, expand its market reach, and strengthen its position as a leader in AI-powered pulmonary health solutions. This collaboration will enable us to enhance interoperability, optimize data-driven decision-making, and scale our impact across healthcare systems globally. Together, we’re unlocking new opportunities to transform respiratory care - making it smarter, faster, and more accessible for all.”

Divya Gupta, Chief Business Officer, Global Health at Qure.ai states, “Low- and middle-income countries bear a disproportionately large burden of lung health issues, cancer, child mortality and infectious disease, on top of a growing shortfall of health workers. These countries see the potential of AI to strengthen health systems but face overwhelming choice and financial constraints. The introduction of QureOS and its growing number of partners, will tackle these challenges via a single platform approach to discover, test and deploy AI within specific ecosystems bridging health inequalities.”

About Qure.ai

Qure.ai is a health tech company that uses deep learning and Artificial Intelligence (AI) to make healthcare more accessible and equitable for patients worldwide. Our solutions power the efficient identification and management of Tuberculosis (TB), Lung Cancer and Stroke to support clinicians and propel developments in the pharmaceutical and medical device industries. We empower healthcare by helping to identify conditions fast, prioritize treatment planning and ultimately improve quality of patient life.  For more information about QureOS please visit qure.ai/product/qureos

About alveofit®

alveofit® is a pioneering digital respiratory health platform committed to transforming global lung care through Al-driven diagnostics, real-time analytics, and connected spirometry solutions. As a fully integrated respiratory care platform designed and made in India, alveofit® gives healthcare providers with precision-driven insights for early disease detection, proactive management, and remote patient monitoring.

Our mission is to enhance access to quality pulmonary care, prevent exacerbations, and improve outcomes for over 300 million individuals worldwide suffering from respiratory conditions.

alveofit® offers an end-to-end, cloud-integrated pulmonary care ecosystem designed for hospitals, clinics, research institutions, and corporate wellness programs. Our loT-enabled smart spirometer seamlessly connects with a digital platform, enabling real-time lung function assessment, Al-powered analytics, and remote patient monitoring. With a strong focus on accessibility, reliability and affordability, alveofit® is bridging healthcare gaps and transforming respiratory care for millions - especially in underserved communities up-to last miles.

See alveofit in your clinic.

A 30-minute demo of oscillometry, spirometry and alveoConnect, on your own patients' workflow.

Book a demo
  1. Acquisition time of 15–30 seconds of tidal breathing per recording, from the alveoflow FOT System specification. Applies to alveoflow Pro and alveoflow Neo.
  2. FHIR R4 and HL7 v2 export from the alveoflow FOT System specification. ABDM integration supported.
  3. CDSCO Class B under MDR 2017. ISO 13485 and MDSAP as stated on alveo.fit. alveoflow: US 510(k) submission pending; not cleared for sale in the United States. alveoair is US FDA 510(k) cleared (K222525, August 2023).
  4. Screens show example data and do not represent a real patient. Interpretation is the responsibility of the treating clinician.